On April 30, 2024, Enlaza Therapeutics (Enlaza), the first covalent biologic platform company, announced it successfully closed a $100 million Series A financing. The round was led by the Life Sciences group of J.P. Morgan Asset Management’s Private Capital division, with participation from existing investors Frazier Life Sciences, Avalon Ventures, Lightspeed Venture Partners, and Samsara BioCapital. The financing also includes new investors Amgen Ventures, Regeneron Ventures, Bregua Corporation, Pappas Capital, and Alexandria Venture Investments. Wilson Sonsini Goodrich & Rosati advised Enlaza on IP matters related to the Series A and represents the company in patent strategy and prosecution matters.

Enlaza's covalent biologic platform, War-Lock™,  generates unique protein drugs that can form stable, covalent bonds with specific drug targets, enhancing efficacy while decreasing toxicity. Proceeds of the financing will be used to further develop Enlaza’s proprietary and groundbreaking covalent protein technologies and to support advancement of wholly owned pipeline programs to the clinic.

The Wilson Sonsini team that advises Enlaza on patent strategy and prosecution matters includes Deborah Smith, Michael Hostetler, Victoria Cheng, Sean Reed, and Jamie Gleason-Bremer.

For more information, please see Enlaza's news release. Additional coverage can be found on BioSpace, BioPharmaDive, and Pharmaceutical Technology.